2. Signaling Pathways
  3. Immunology/Inflammation
  4. NO Synthase
  5. NO Synthase Antagonist

NO Synthase Antagonist

NO Synthase Isoform Comparison

NO Synthase Antagonists (4):

Cat. No. Product Name Effect Purity
  • HY-141411A
    Zevaquenabant
    		Antagonist
    Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual cannabinoid CB1 receptor and inducible NOS antagonist. Zevaquenabant ameliorates obesity-induced chronic kidney disease (CKD).
  • HY-18732B
    L-NMMA citrate
    		Antagonist
    L-NMMA citrate competitively antagonizes L-arginine, and thus inhibits production of nitric oxide (NO). L-NMMA is utilized as NO synthase antagonist in experimental settings.
  • HY-18732C
    L-NMMA hydrochloride
    		Antagonist
    L-NMMA (Tilarginine) hydrochloride competitively antagonizes L-arginine, and thus inhibits production of nitric oxide (NO). L-NMMA hydrochloride is utilized as NO synthase antagonist in experimental settings.
  • HY-18732
    L-NMMA
    		Antagonist
    L-NMMA (Tilarginine; Methylarginine) competitively antagonizes L-arginine, and thus inhibits production of nitric oxide (NO). L-NMMA is utilized as NO synthase antagonist in experimental settings.